Valuation : iTeos Therapeutics, Inc.

Market Cap 449M 387M 363M 331M 623M 42.88B 625M 4.3B 1.68B 21.65B 1.68B 1.65B 71.78B P/E 2023
-3.48x
P/E 2024 -2.31x
Enterprise Value -40.87M -35.22M -33.02M -30.14M -56.78M -3.91B -56.96M -392M -153M -1.97B -153M -150M -6.54B EV / Sales 2023
-10,640,152x
EV / Sales 2024 -5,970,615x
Free-Float
100%
Yield 2023 *
-
Yield 2024 -
3 years 4.8
Extreme 4.8
18.75
5 years 4.8
Extreme 4.8
52.43
10 years 4.8
Extreme 4.8
52.43
Manager TitleAgeSince
Chief Executive Officer 59 2025-08-27
Chief Operating Officer - 2025-08-27
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 59 2025-08-27
Date Insider Type Main position Quantity % Market Cap.
8/29/25 Tender

Chief Technology Officer

222,423 0.5811%
8/29/25 Tender

Chief Executive Officer; Director

1,106,638 2.8914%
8/29/25 Tender

Chief Operating Officer

578,671 1.5119%
Change 5-day change 1-year change 3-year change Capi.($)
+0.20%-.--%-.--%-17.41% 449M
-1.59%-3.35%+64.49%+98.69% 69.54B
-1.34%-0.75%+48.56%+90.63% 64.97B
-8.37%-12.43%+0.14%-15.42% 25.64B
-2.35%-5.75%-12.17%+448.29% 25.89B
+0.30%-0.69%+63.18%+11.93% 26.51B
-0.96%+10.36%+278.86%+438.78% 20.22B
-0.51%+0.23%+33.71%-18.02% 19.98B
-1.91%-4.37%+13.33%+531.29% 15.69B
-1.47%+0.68%+43.67%+145.49% 13.49B
Average -1.80%-1.73%+53.38%+171.42% 28.24B
Weighted average by Cap. -1.93%-1.50%+57.06%+152.55%

Financials

2023 2024
Net sales 12.6 10.85 10.18 9.29 17.5 1.2K 17.55 120.73 47.1 607.65 47.29 46.26 2.01K 35 30.16 28.28 25.81 48.63 3.35K 48.78 335.49 130.9 1.69K 131.41 128.55 5.6K
Net income -113M -97.06M -91.01M -83.08M -157M -10.77B -157M -1.08B -421M -5.43B -423M -414M -18.02B -134M -116M -109M -99.13M -187M -12.85B -187M -1.29B -503M -6.48B -505M -494M -21.5B
Net Debt -526M -453M -425M -388M -731M -50.26B -733M -5.04B -1.97B -25.37B -1.97B -1.93B -84.12B -490M -422M -396M -361M -680M -46.79B -682M -4.69B -1.83B -23.62B -1.84B -1.8B -78.32B
Logo iTeos Therapeutics, Inc.
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448/GSK4428859A, is an antagonist of TIGIT, an immune checkpoint with multiple mechanisms of action. Its EOS-984, a potentially first-in-class small molecule, focused on a new mechanism in the adenosine pathway by targeting equilibrative nucleoside transporter 1, a dominant transporter of extracellular adenosine, expressed on intratumoral T cells, which allows adenosine entry into the cell, disturbing T cell metabolism, expansion, effector function, and survival. It is also developing EOS-215, a potential best-in-class monoclonal antibody which antagonizes the triggering receptor expressed on myeloid cells 2.
Employees
173
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. ITOS Stock